HSBC drops blunt verdict on 150-year-old dividend stock
Eli Lilly has spent the last decade transforming from a reliable but unremarkable dividend payer into one of the most talked-about stocks on Wall Street. Its obesity and diabetes franchise, built around tirzepatide, the active ingredient in both Zepbound and Mounjaro, has sent the dividend stock soaring and reshaped how investors think about the pharmaceutical
